Elicio Therapeutics (ELTX) FCF Margin (2020 - 2022)

Elicio Therapeutics (ELTX) has reported FCF Margin for 3 consecutive years, with 849.77% the latest figure, recorded in Q2 2022.

• For the quarter ending Q2 2022, FCF Margin rose 284255.0% year-over-year to 849.77%; the trailing twelve-month figure through Mar 2023 stood at 2320.06% (down 213065.0% YoY), and the FY2022 full-year result was 992.31%, down 80502.0% from the prior year.
• FCF Margin advanced to 849.77% in Q2 2022 per ELTX's latest filing, from 948.12% in the prior quarter.
• Across five years, FCF Margin topped out at 4483.88% in Q4 2020 and bottomed at 3397.84% in Q1 2021.
• Historically, FCF Margin has averaged 752.88% across 3 years, with a median of 1028.56% in 2021.
• The sharpest annual moves came in 2021 and 2022: FCF Margin sank 453938 bps in 2021, then surged 284255 bps in 2022.
• Over 3 years, FCF Margin stood at 4483.88% in 2020, then plunged by 101 bps to 55.5% in 2021, then soared by 1631 bps to 849.77% in 2022.
• According to Business Quant data, FCF Margin over the past three periods registered 849.77%, 948.12%, and 55.5% for Q2 2022, Q1 2022, and Q4 2021 respectively.